Page 206 - Read Online

factor-beta type II receptor (TGF-beta RII) expression in 31. Brekken RA, Overholser JP, Stastny VA, Waltenberger J,
adenocarcinoma of the lung. Anticancer Res 1999;19:301-6. Minna JD, Thorpe PE. Selective inhibition of vascular
16. Grady WM, Myeroff LL, Swinler SE, Rajput A, endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1)
Thiagalingam S, Lutterbaugh JD, Neumann A, Brattain MG, activity by a monoclonal anti-VEGF antibody blocks tumor
Chang J, Kim SJ, Kinzler KW, Vogelstein B, Willson JK, growth in mice. Cancer Res 2000;60:5117-24.
Markowitz S. Mutational inactivation of transforming growth 32. Prewett M, Huber J, Li Y, Santiago A, O’Connor W,
factor beta receptor type II in microsatellite stable colon King K, Overholser J, Hooper A, Pytowski B, Witte L,
cancers. Cancer Res 1999;59:320-4. Bohlen P, Hicklin DJ. Antivascular endothelial growth factor
17. Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, receptor (fetal liver kinase 1) monoclonal antibody inhibits
Kinzler KW, Vogelstein B. Microsatellite instability tumor angiogenesis and growth of several mouse and human
and mutations of the transforming growth factor beta tumors. Cancer Res 1999;59:5209-18.
type II receptor gene in colorectal cancer. Cancer Res 33. Hynes NE, Lane HA. ERBB receptors and cancer:
1995;55:5548-50. the complexity of targeted inhibitors. Nat Rev Cancer
18. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, 2005;5:341-54.
Kern SE. Genetic alterations of the transforming growth factor 34. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of
beta receptor genes in pancreatic and biliary adenocarcinomas. trastuzumab resistance. Breast Cancer Res 2006;8:215.
Cancer Res 1998;58:5329-32. 35. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ.
19. Walter JW, North PE, Waner M, Mizeracki A, Blei F, Insulin-like growth factor-I receptor/human epidermal
Walker JW, Reinisch JF, Marchuk DA. Somatic mutation growth factor receptor 2 heterodimerization contributes to
of vascular endothelial growth factor receptors in juvenile trastuzumab resistance of breast cancer cells. Cancer Res
hemangioma. Genes Chromosomes Cancer 2002;33:295-303. 2005;65:11118-28.
20. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfi eld EH, 36. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M,
Aaronson SA, Ali IU. Amplifi cation and/or overexpression Molinari F, De Dosso S, Saletti P, Martini M, Cipani T,
of platelet-derived growth factor receptors and epidermal Marrapese G, Mazzucchelli L, Lamba S, Veronese S,
growth factor receptor in human glial tumors. Cancer Res Frattini M, Bardelli A, Siena S. Multi-determinants analysis
1992;52:4550-3. of molecular alterations for predicting clinical benefi t to
21. Tornillo L, Terracciano LM. An update on molecular EGFR-targeted monoclonal antibodies in colorectal cancer.
genetics of gastrointestinal stromal tumours. J Clin Pathol PLoS One 2009;4:e7287.
2006;59:557-63. 37. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R,
22. Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Ludwig DL, Plymate SR. In vivo effects of the human
Coutre SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase type I insulin-like growth factor receptor antibody A12 on
in hypereosinophilic syndrome and chronic eosinophilic androgen-dependent and androgen-independent xenograft
leukemia: Implications for diagnosis, classifi cation, and human prostate tumors. Clin Cancer Res 2005;11:3065-74.
management. Blood 2004;103:2879-91. 38. Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK,
23. Cheung YH, Gayden T, Campeau PM, LeDuc CA, Lee HY. Implication of the insulin-like growth factor-IR
Russo D, Nguyen VH, Guo J, Qi M, Guan Y, Albrecht S, pathway in the resistance of non-small cell lung cancer
Moroz B, Eldin KW, Lu JT, Schwartzentruber J, Malkin D, cells to treatment with gefi tinib. Clin Cancer Res
Berghuis AM, Emil S, Gibbs RA, Burk DL, Vanstone M, 2007;13:2795-803.
Lee BH, Orchard D, Boycott KM, Chung WK, Jabado N. 39. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R.
A recurrent PDGFRB mutation causes familial infantile Insulin-like growth factor receptor as a therapeutic target in
myofi bromatosis. Am J Hum Genet 2013;92:996-1000. head and neck cancer. Clin Cancer Res 2007;13:4291-9.
24. Haugsten EM, Wiedlocha A, Olsnes S, Wesche J. Roles of 40. Slomiany MG, Black LA, Kibbey MM, Tingler MA, Day TA,
fi broblast growth factor receptors in carcinogenesis. Mol Rosenzweig SA. Insulin-like growth factor-1 receptor and
Cancer Res 2010;8:1439-52. ligand targeting in head and neck squamous cell carcinoma.
25. Turner N, Grose R. Fibroblast growth factor signalling: from Cancer Lett 2007;248:269-79.
development to cancer. Nat Rev Cancer 2010;10:116-29. 41. Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR,
26. Grose R, Dickson C. Fibroblast growth factor signaling in Goodman-Davis N, Hollywood E, Shia J, Schwartz J,
tumorigenesis. Cytokine Growth Factor Rev 2005;16:179-86. Chandrawansa K, Dontabhaktuni A, Youssoufi an H,
27. Adams GP, Weiner LM. Monoclonal antibody therapy of Solit DB, Saltz LB. Randomized, phase II study of the
cancer. Nat Biotechnol 2005;23:1147-57. insulin-like growth factor-1 receptor inhibitor IMC-A12,
28. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, with or without cetuximab, in patients with cetuximab- or
Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, panitumumab-refractory metastatic colorectal cancer. J Clin
Burchmore M, Shak S, Stewart SJ, Press M. Effi cacy and Oncol 2010;28:4240-6.
safety of trastuzumab as a single agent in fi rst-line treatment 42. Arcaro A. Targeting the insulin-like growth factor-1 receptor
of HER2-overexpressing metastatic breast cancer. J Clin in human cancer. Front Pharmacol 2013;4:30.
Oncol 2002;20:719-26. 43. Workman P, Brunton VG, Robins DJ. Tyrosine kinase
29. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, inhibitors. Semin Cancer Biol 1992;3:369-81.
Stavrou D, Westphal M, Lamszus K. Inhibition of glioma 44. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in
angiogenesis and growth in vivo by systemic treatment with cancer therapy. J Pharmacol Exp Ther 2005;315:971-9.
a monoclonal antibody against vascular endothelial growth 45. Carboni JM, Wittman M, Yang Z, Lee F, Greer A, Hurlburt W,
factor receptor-2. Cancer Res 2001;61:6624-8. Hillerman S, Cao C, Cantor GH, Dell-John J, Chen C,
30. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Discenza L, Menard K, Li A, Trainor G, Vyas D, Kramer R,
Bosch J. Anti-VEGF receptor-2 monoclonal antibody Attar RM, Gottardis MM. BMS-754807, a small molecule
prevents portal-systemic collateral vessel formation in portal inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther
hypertensive mice. Gastroenterology 2004;126:886-94. 2009;8:3341-9.

Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 3 ¦ October 15, 2015 ¦ 199